[CAS NO. 56211-40-6] Torsemide

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [56211-40-6]

Catalog

HY-B0247

Brand

MCE

CAS

56211-40-6

DESCRIPTION [56211-40-6]

Overview

MDL	MFCD00866166
Molecular Weight	348.42
Molecular Formula	C16H20N4O3S
SMILES	O=S(C1=C(NC2=CC=CC(C)=C2)C=CN=C1)(NC(NC(C)C)=O)=O

For research use only. We do not sell to patients.

Summary

Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis ^[1] ^[1] ^[3] .

In Vitro

Torsemide binds reversibly to Na ⁺ /2Cl ^- /K ⁺ cotransporter carrier protein, thus reducing or abolishing NaCl reabsorption ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00602303	Roxane Laboratories\|West-Ward Pharmaceutical	Edema	September 2003	Not Applicable
NCT05093621	Yale University	Heart Failure	February 8, 2021	Phase 3
NCT02813551	The University of Texas Health Science Center, Houston	Preeclampsia	August 2016	Phase 2
NCT01558674	Merck Sharp & Dohme LLC	Renal Impairment\|Heart Failure	May 23, 2014	Phase 1
NCT00602615	Roxane Laboratories\|West-Ward Pharmaceutical	Edema	September 2003	Not Applicable
NCT01788254	Matthias Schwab\|University Hospital Tuebingen	Genotype-related Drug Metabolism	January 2012	Phase 1
NCT00409942	Ferrer Internacional S.A.	Congestive Heart Failure	March 2007	Phase 4
NCT01942109	Medical University of Warsaw	Heart Failure	September 2013	Phase 4
NCT03509545	Sarfez Pharmaceuticals, Inc.	Body Weight Changes	June 30, 2021	Phase 1
NCT03354897	NHS Greater Glasgow and Clyde\|University of Glasgow\|British Heart Foundation	Cardiovascular Diseases\|Hypertension	April 5, 2017	Phase 4
NCT02087332	Society of Specialists in Heart Failure	Arterial Hypertension\|Chronic Heart Failure	April 2014	Phase 4
NCT01276288	Boehringer Ingelheim	Diabetes Mellitus, Type 2	January 2011	Phase 1
NCT04921566	Pharmtechnology LLC\|ClinPharmInvest, LLC	Bioequivalence	June 5, 2021	Phase 1
NCT03215875	Sarfez Pharmaceuticals, Inc.	Food-drug Interaction	October 17, 2017	Phase 1
NCT01845194	Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH	Drug Biotransformation\|Membrane Transport	December 2009	Phase 1
NCT03214874	Sarfez Pharmaceuticals, Inc.	Congestive Heart Failure\|Chronic Kidney Diseases	June 19, 2017	Phase 1
NCT03187509	New York City Health and Hospitals Corporation	Heart Failure	April 17, 2018	Phase 4
NCT00654043	Par Pharmaceutical, Inc.\|Anapharm	Healthy	April 2001	Phase 1
NCT00653549	Par Pharmaceutical, Inc.\|Anapharm	To Determine Bioequivalence Under Fasting Conditions	April 2001	Phase 1
NCT00334386	Ferrer Internacional S.A.	Hypertension	April 2005	Phase 4
NCT03296813	Duke University\|National Heart, Lung, and Blood Institute (NHLBI)\|Yale University	Heart Failure	July 11, 2018	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL ( 71.75 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8701 mL	14.3505 mL	28.7010 mL
5 mM	0.5740 mL	2.8701 mL	5.7402 mL
10 mM	0.2870 mL	1.4350 mL	2.8701 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 1 mg/mL (2.87 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 1 mg/mL (2.87 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 1 mg/mL (2.87 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

3-Pyridinesulfonamide, N-[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-

N-[[(1-Methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide

Torasemide

AC 4464

BM 02015

Torsemide

Luprac

Demadex

Torem

Toradiur

Unat

JDL 464

BM 02.015

Dilutol

Tide 10

Examide

1-([4-[(3-Methylphenyl)amino]pyridin-3-yl]sulfonyl)-3-(propan-2-yl)urea

1-[4-(3-Methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea

UpCard

Isemid